Pharmacological treatment of borderline personality disorder;Tratamiento farmacológico del trastorno límite de personalidad

Salud Mental

Volumn 29, Issue 5, 2006, Pages 16-24

  Chávez León, Enrique ^a,b   Ng, Bernardo ^c,d   Ontiveros Uribe, Martha Patricia ^a,e  

^a Asociación Psiquiátrica Mexicana   (Mexico)

^b UNIVERSIDAD ANÁHUAC   (Mexico)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Centro Médico Sun Valley Behavioral   (United States)

^e INSTITUTO NACIONAL DE PSIQUIATRÍA RAMÓN DE LA FUENTE MUÑIZ   (Mexico)

Author keywords

Aggression; Borderline personality disorder; Carbamazepine; Fluoxetine; Olanzapine; Topiramate; Valproate

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CLOZAPINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; MONOAMINE OXIDASE INHIBITOR; OLANZAPINE; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

ANXIETY DISORDER; AUTOMUTILATION; BORDERLINE STATE; CHILDHOOD; CLINICAL FEATURE; COPING BEHAVIOR; DEPRESSION; EGO DEVELOPMENT; HUMAN; MENTAL INSTABILITY; MOOD DISORDER; NEUROSIS; PERSONALITY DISORDER; PSYCHOPATHY; PSYCHOSIS; REVIEW; SELF CONCEPT; SEXUAL ABUSE; SUBSTANCE ABUSE; TEMPERAMENT;

EID: 33845328452     PISSN: 01853325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. ADELMAN SA: Pills as transitional objects: a dynamic understanding of the use of medication in psychotherapy, Psychiatry, 48(3)246-53, 1985.
2. AMERICAN PSYCHIATRIC ASSOCIATION: DSM- IV. Diagnostic and Statistical Manual of Mental Disorders. Cuarta edición. Washington, 1994.
3. ASOCIACION PSIQUIATRICA AMERICANA: DSM-IV-TR. Manual Diagnóstico y Estadístico de los Trastornos Mentales. Cuarta edición. Texto revisado. Masson, Barcelona, 2002.
4. BARRET E, BLONDE L, CLEMENT S y cols.: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27(2):596-601, 2004.
5. BENDER DS, DOLAN RT, SKODOL AE y cols.: Treatment utilization by patients with personality disorder. Am J Psychiatry, 158(2):295-302, 2001.
6. BERLIN HA, ROLLS ET, IVERSEN SD: Borderline personality disorder, impulsivity, and the orbitofrontal cortex. Am J Psychiatry, 162:2360-2373, 2005.
7. BEST M, WILLIAMS JM, COCCARO EF: Evidence for a dysfunctional prefrontal circuit in patients with an impulsive aggressive disorder. Proc Natl Acad Sci USA, 99:8448-8453, 2002.
8. BLEULER EP: Textbook of Psychiatry. Macmillan, USA, 1924.
9. BOGENSCHUTZ MP, NURNBERG HG: Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry, 65(1):104-109, 2004.
10. CASSANO P, LATANZZI L, PINI S y cols.: Topiramate for self-mutilation in a patient with borderline personality disorder. Bipolar Disord, 3(3):42-53, 1999.
11. CHAVEZ-LEON E, ONTIVEROS-URIBE M, LOPEZ-GARZA D, NG B: Trastornos de la personalidad. En: Manual de Trastornos Mentales. Asociación Psiquiátrica Mexicana, México, 2005.
12. CHENGAPPA KP, EBELING T, KANG JS y cols.: Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder J Clin Psychiatry, 60(7):477-484, 1999.
13. COCCARO EF: Family history study of intermittent explosive disorder. En: New Research Program and Abstracts. American Psychiatric Association 152nd Annual Meeting. Washington, 1999.
14. COCCARO EF, BERGEMAN CS, KAVOUSSI RJ: Heritability of aggression and irritability: a twin study of the Buss-Durkee aggression scales in adult male subjects. Biol Psychiatry, 41:273-284, 1997.
15. COCCARO EF, KAVOUSSI RJ: Fluoxetine and impulsive aggressive behavior in personality- disordered subjects. Arch Gen Psychiatry, 54:1081-1088, 1997.
16. COWDRY RW, GARDNER DL: Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry, 45:111-119, 1988.
17. CRITCHFIELD KL, LEVY KN, CLARKIN JF: The relationship between impulsivity, aggression, and impulsive aggression in borderline personality disorder: an empirical analysis of self-report measures. J Personality Dis, 18(6):555-570, 2004.
18. DAHL AA: Some aspects of DSM-III personality disorders illustrated by a consecutive simple of hospitalized patients. Acta Psychiatr Scand (Supl) 328:61-67, 1986.
19. DEPUE RA, LENZENWEGER MF: A neurobehavioral dimensional model. En: Livesley WJ (Ed). Handbook of Personality Disorders. Guilford, Nueva York, 2001.
20. DRIESSEN M, HERMANN J, STAHL K y cols.: Magnetic resonance volume of the hippocampus and the amygdala in women with borderline personality disorder and early traumatization. Arch Gen Psychiatry, 57:1115-1122, 2000.
21. FERRERI MM, LOZE JY, ROUILLON F y cols.: Clozapine treatment of a borderline personality disorder with severe self-mutilating behaviors. Eur Psychiatry, 19(3):177-178, 2004.
22. FORMAN EM, BERK MS, HENRIQUES GR y cols.: History of multiple suicidal attempts as a behavioral marker of severe psychopathology. Am J Psychiatry, 161:437-443, 2004.
23. FOSSATI A, MAFFEI C, BAGNATO M y cols.: Patterns of covariation of DSM- IV personality disorders in a mixed psychiatric sample, Compr Psychiatry, 41:206-215, 2000.
24. FRANKENBURG FR, ZANARINI MC: Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double blind placebo- controlled pilot study. J Clin Psychiatry, 63:442-446, 2002.
25. GABBARD GO: Mind, brain, and personality disorders. Am J Psychiatry, 162:648-655, 2005.
26. GITLIN MJ: Pharmacotherapy of personality disorders: conceptual framework and clinical strategies. J Clin Psychopharmacol, 13(5):343-353, 1993.
27. GRILO CM, MCGLASHAN TH, QUINLAN DM y cols.: Frequency of personality disorders in two age cohorts of psychiatric inpatients. Am J Psychiatry, 155:140-142, 1998.
28. GUNDERSON JG, SABO AN: The phenomenological and conceptual interface between borderline personality disorder and PTSD. Am J Psychiatry, 150:19-27, 1993.
29. HERMAN JL, PERRY JC, VAN DER KOLK BA: Childhood trauma in borderline personality. Am J Psychiatry, 146:490-95, 1989.
30. HERPERTZ SC, DIETRICH TM, WENNING B: Evidence of abnormal amygdala functioning in borderline personality disorder. A functional MRI study. Biol Psychiatry, 50:292-298, 2001.
31. HILGER E, BARNES C, KASPER S: Quetiapine in the treatment of borderline personality disorder. World J Biol Psychiatry, 4(1):42-44, 2003.
32. HOLLANDER E, ALLEN A, LOPEZ RP y cols.: A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality. J Clin Psychiatry, 62(3):199-203, 2001.
33. HOLLANDER E, SWAN AC, COCCARO EF y cols.: Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry, 162:621-24, 2005.
34. IRLEA E, LANGEA C, SACHSSEB U: Reduced size and abnormal asymmetry of parietal cortex in women with borderline personality disorder: a functional MRI study. Biol Psychiatry, 50:292-8, 2005.
35. JOYCE PR, MULDER RT, LUTY SE y cols.: Borderline personality disorder in major depression: symptomatology, temperament, character, differential drug response, and 6-month outcome. Compr Psychiatry, 44(1):35-43, 2003.
36. KASS F, SKODOL AE, CHARLES E y cols.: Scaled ratings of DSM- III personality disorders. Am J Psychiatry, 142:627-30, 1985.
37. KOENIGSBERG HW, KAPLAN RD, GILMORE MM, COOPER AM: The relationship between syndrome and personality disorder in DSM- III: experience with 2,462 patients. Am J Psychiatry, 142:207-12, 1985.
38. LIN PY, TSAI G: Association between serotonin transporter gene promoter polymorphism and suicide: results of a meta-analysis. Biol Psychiatry, 55:1023-30, 2004.
39. LINEHAN MM: Cognitive-Behavioural Treatment of Borderline Personality Disorder. Guilford Press, Nueva York, 1993.
40. LINKS P, STEINER M, BOIAGO I, IRWIN D: Lithium therapy for borderline patients: preliminary findings. J Personal Disord, 4:173-81, 1990.
41. LIVESLEY WJ, JANG KL, VERNON PA: Phenotypic and genetic structure of traits delineating personality disorder. Arch Gen Psychiatry, 55:941-48, 1998.
42. MARINANGELI MG, BUTTI G, SCINTO A y cols.: Patterns of Comorbidity among DSM- III- R personality disorders. Psychopathology, 33:69-74, 2000.
43. MARKOVITZ PJ: Recent trends in the pharmacotherapy of personality disorder. J Personal Disord, 18(1):90-101, 2004.
44. MARKOVITZ PJ, WAGNER SC: Venlafaxine in the treatment of borderline personality disorder. Psychopharmacol Bull, 31(4):773-7, 1995.
45. MCLEAN LM, GALLOP R: Implications of childhood sexual abuse for adult borderline personality disorder and complex post traumatic stress disorder. Am J Psychiatry, 160:369-71, 2003.
46. MILLER FT, ABRAMS T, DULIT R: Substance abuse in borderline personality disorder. Am J Drug Alcohol Abuse, 19(4):491-97, 1993.
47. MILLON T: Trastornos de la Personalidad. Masson, Barcelona, 1998.
48. NEW AS, HAZLETT EA, BUSCHSBAUM MS: Blunted pre-frontal cortical 18-fluorordeoxiglucose positron emission tomography response to meta- chlorophenylpiperazine in impulsive aggression. Arch Gen Psychiatry, 59:621-9, 2002.
49. NEW AS, TRESTMAN RL, MITROPOULOU V: Serotoninergic function and self- injurious behavior in personality disorder patients. Psychiatry Res, 69:17-26, 1997.
50. NEW AS, YEHUDA R, STEINBERG B y cols.: Self-reported abuse and biological measures in personality disorders. Biol Psychiatry, 39:535, 1996.
51. NEWTON-HOWES G, TYRER P: Pharmacotherapy of personality disorders. Expert Opin Pharmacother, 4(10):1643-9, 2003.
52. NICKEL MK, NICKEL C, KAPLAN P y cols.: Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry, 57:495-9, 2005.
53. OLDHAM JM, PHILLIPS KA, GABBARD GO y cols: Practice guideline for the treatment of patients with borderline personality disorder. Am J Psychiatry (Supl), 158(10):1-52, 2001.
54. OLDHAM JM, SKODOL AE, KELLMAN HD y cols.: Comorbidity of axis I and axis II disorders. Am J Psychiatry, 152:571-8, 1995.
55. OTTOSSON H, BODLUND O, EKSELIUS L Y COLS: DSM- IV and ICD- 10 personality disorders: a comparison of a self-report questionnaire (DIP-Q) with a structured interview. Eur Psychiatry, 13:246-253, 1998.
56. PARIS J, ZWEIG-FRANK H, NG F y cols.: Neurobiological correlates of diagnosis and underlying traits in patients with borderline personality disorder compared with normal controls. Psychiatry Res, 121:239-52, 2004.
57. PARSONS B, QUITKING FM, MCGRATH PJ y cols.: Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacol Bull, 25(4):524-534, 1989.
58. PASCUAL JC, OLLER S, SOLER J y cols.: Ziprasidone in the acute treatment of borderline personality disorder in psychiatric emergency services. J Clin Psychiatry, 65(9):1281-2, 2004.
59. PINTO OC, AKISKAL HS: Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder. J Affect Disord, 51(3):333-43, 1998.
60. PRESTON GA, MARCHANT BK, REIMHERR FW y cols.: Borderline personality disorder in patients with bipolar disorder and response to lamotrigine. J Affect Disord, 79:297-303, 2004.
61. RAJ YP: Psychopharmacology of borderline personality disorder. Curr Psychiatry Rep, 6(3):225-31, 2004.
62. RINNE T, VAN DEN BRINK W, WOUTERS L, VAN DICK R: SSRI treatment of borderline personality disorder: a randomized placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry, 159:2048-54, 2002.
63. RUSELL JM, KORNSTEIN SG, SHEA MT y cols.: Chronic depression and comorbid personality disorders: response to sertraline vs imipramine. J Clin Psychiatry, 64:554-61, 2003.
64. SALZMAN C, WOLFSON A, SCHATZBERG A y cols.: Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacology, 15:23-9, 1995.
65. SANSONE RA, RYTWINSKI D, GAITHER GA: Borderline personality and psychotropic medication prescription in an outpatient clinic. Compr Psychiatry, 44(6):454-8, 2003.
66. SCHATZBERG AF, NEMEROFF CB: Textbook of Psychopharmacology. American Psychiatric Press, Washington, 1995.
67. SIEVER LJ, DAVIS KL: Psychobiological perspectives on the personality disorders. Am J Psychiatry, 148:1647-58, 1991.
68. SIMPSON EB, YEN S, COSTELLO E y cols.: Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. J Clin Psychiatry, 65:379-85, 2004.
69. SOLOFF PH: Is there any drug treatment of choice for the borderline patient? Acta Psychiatr Scand, 379(Supl.):50-5, 1994.
70. SOLOFF PH: Special features: psychobiologic perspectives on treatment of personality disorders. J Personal Disord, 11(4):336-44, 1997.
71. SOLOFF PH: Psychopharmacology of borderline personality disorder. Psychiatr Clin North Am, 23(1):169-92, 2000.
72. SOLOFF PH, CORNELIUS J, GEORGE A y cols: Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry, 50:377-85, 1993.
73. SOLOFF PH, GEORGE A, NATHAN S y cols.: Amitriptyline versus haloperidol in borderlines. J Clin Psychopharmacol, 43:238-46, 1989.
74. STANGL D, PFOHL B, ZIMMERMAN M y cols.: A structured interview for the DSM- III personality disorders: a preliminary report. Arch Gen Psychiatry, 42:591-6, 1985.
75. STONE MH: Treatment of borderline patients: a pragmatic approach. Psychiatr Clin North Am, 13(2):265-85, 1990.
76. TORGENSEN S: Genetic and nosological aspects of schizotypal and borderline personality disorders. Arch Gen Psychiatry, 41:546-54, 1984.
77. TORGENSEN S, LYGREN S, OIEN PA y cols.: A twin study of personality disorders. Compr Psychiatry, 41:416-25, 2000.
78. VAN ELST LT, THIEL T, HESSLINGER B y cols.: Subtle prefrontal neuropathology in a pilot magnetic resonance spectroscopy study in patients with borderline personality disorder. J Neuropsychiatry Clin Neurosci, 13:511-14, 2001.
79. WHITE CN, GUNDERSON JG, ZANARINI MC, HUDSON JI: Family studies of borderline personality disorder: a review. Harv Rev Psychiatry, 11:8-19, 2003.
80. ZANARINI MC: Childhood experiences associated with the development of borderline personality disorder. Psychiatr Clin North Am, 23:89-101, 2000.
81. ZANARINI MC, FRANKENBURG FR: Olanzapine treatment of female borderline personality disorder patients. J Clin Psychiatry, 62:849-54, 2001.
82. ZANARINI MC, FRANKENBURG FR, PARACHINI EA: A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine- fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry, 65:903-7, 2004.
83. ZIMMERMAN M, ROTHSCHILD L, CHELMINSKI I: The prevalence of DSM- IV personality disorders in psychiatric outpatients. Am J Psychiatry, 162:1911-8, 2005.
84. ZISOOK S, RICKETTS JE: Psychopharmacologic approaches to the borderline patient. Hillside J Clin Psychiatry, 10:55-70, 1988.